# Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

> **NCT03589729** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 100 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Blasts 10 Percent or More of Bone Marrow Nucleated Cells
- High Risk Myelodysplastic Syndrome
- Myeloid Sarcoma
- Myeloproliferative Neoplasm
- Philadelphia Chromosome Positive

## Interventions

- **DRUG:** Cladribine
- **DRUG:** Cytarabine
- **DRUG:** Dexrazoxane Hydrochloride
- **DRUG:** Gemtuzumab Ozogamicin
- **DRUG:** Idarubicin

## Key facts

- **NCT ID:** NCT03589729
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-09-19
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03589729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03589729, "Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03589729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*